Work

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps4220

Authors: Xiangcheng Li, Changxian Li, Yuan Cheng, Bin Zhang, Yonghua Xu

Institutions: Jiangsu Province Hospital, Nanjing Medical University, Nanjing General Hospital of Nanjing Military Command, Nanjing University, Affiliated Hospital of Xuzhou Medical College, Yancheng First People's Hospital

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410814448

FWCI:

Cites:

Cited by:

Related to: 10